Mårten Falkenberg/ Vascular News
Aug 31, 2025, 07:12
Late-Breaking SWEDEPAD Trial Finds No Benefit of Drug-Coated Balloons and Stents, Raises Safety Concerns
Vascular News shared an important post on LinkedIn:
“BREAKING NEWS: Drug-coated balloons and stents were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in the SWEDEPAD 1 and 2 trials. In addition, higher five-year mortality with drug-coated devices in patients with intermittent claudication was noted, leading researchers to stress that the safety of paclitaxel-coated devices is an “ongoing discussion”.
These late-breaking findings were presented today at the European Society of Cardiology (ESC) 2025 congress (29 August–1 September, Madrid, Spain) and simultaneously published in The Lancet Group.”
Read more here.
Stay updated with Hemostasis Today.
-
Jun 8, 2026, 06:30Caryn Blumenfeld: Team Zakophilia and Ratner’s Runners Even Though It’s A Walk!
-
Jun 8, 2026, 06:25Cécile Jefford: The NEHA Community and the Power of Human Connection
-
Jun 8, 2026, 06:02Manoj K: How Incyte Could Help Transform Care for Patients With von Willebrand Disease
-
Jun 8, 2026, 03:05Shamsunisha Yusuff: Iron Down, Platelets Up in a Young CBC ?
-
Jun 8, 2026, 03:03Samwel Mikaye: D-Dimer – A Marker of Blood Clot Breakdown
-
Jun 8, 2026, 02:59Vinita Madhuri: Our Engagement, A Lifeline for Thalassemia Patients
-
Jun 7, 2026, 22:11Lucia Härtel: Exercise, IL-10 Signaling, and Post-Stroke Brain Plasticity
-
Jun 7, 2026, 19:35Ashish Pemawat: Is the 4.5-Hour Thrombolysis Window Becoming Less Relevant?
-
Jun 7, 2026, 18:25Nita Radhakrishnan: Every Child Cured Is a Reminder of What Can Be Achieved When We Work Together